TScan Therapeutics, Inc.(TCRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,874 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in TCRX
Events flagged as statistical outliers against TCRX's own multi-year baseline — not fixed dollar thresholds.
TCRX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for TScan Therapeutics, Inc. (TCRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TCRX at 13.9/100 on a 32-signal composite quality model, placing it at rank #2,874 of 2,962 stocks — the bottom half of the AI-ranked universe. TCRX scores in the top quartile across institutional flow (91.0). Areas of concern include free cash flow (1.4) and revenue scale (1.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TScan Therapeutics, Inc. reports quarterly revenue of $1.1M, net income of $-30.4M, free cash flow of $-28.0M. Top institutional holders of TCRX by reported 13-F value include Lynx1 Capital Management, BVF, BAKER BROS. ADVISORS, based on the most recent SEC filings. TCRX trades on the Nasdaq exchange and files with the SEC under CIK 1783328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TCRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TScan Therapeutics, Inc. directly from SEC EDGAR. TScan Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 28 since 2022, currently 13.9 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.1M
Net Income
Q2 2026
$-30.4M
Free Cash Flow
Q2 2026
$-28.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+266.7% YoYNet Income
-1.8% YoYOperating Income
-0.7% YoYEPS (Diluted)
+12.3% YoYTotal Assets
-38.4% YoYTotal Debt
+1.4% YoYOp. Cash Flow
-22.1% YoYFree Cash Flow
-21.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $10.3M +266.7% | $2.8M -86.6% | $21.0M +55.5% | $13.5M +33.5% | $10.1M +834.7% | $1.1M |
| Net Income | $-129.8M -1.8% | $-127.5M -42.9% | $-89.2M -34.7% | $-66.2M -36.2% | $-48.6M -86.1% | $-26.1M |
| Operating Income | $-135.8M -0.7% | $-134.8M -44.3% | $-93.5M -40.3% | $-66.6M -37.0% | $-48.6M -85.4% | $-26.2M |
| EPS (Diluted) | $-1.00 +12.3% | $-1.14 +16.2% | $-1.36 +50.5% | $-2.75 +34.1% | $-4.17 | — |
| Total Assets | $228.8M -38.4% | $371.1M +36.4% | $272.1M +36.7% | $199.1M +5.8% | $188.1M +278.2% | $49.7M |
| Total Debt | $32.5M +1.4% | $32.1M -4.0% | $33.4M +14.0% | $29.3M | — | — |
| Operating Cash Flow | $-135.3M -22.1% | $-110.8M -80.6% | $-61.4M +7.7% | $-66.5M -36.6% | $-48.7M -1510.2% | $-3.0M |
| Free Cash Flow | $-139.7M -21.9% | $-114.6M -77.7% | $-64.5M +8.8% | $-70.7M -20.7% | $-58.6M -707.3% | $-7.3M |
Get alerted when TCRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for TScan Therapeutics, Inc. including:
Top Institutional Holders of TCRX
Lynx1 Capital Management LP
$7.9M8,019,148 shBVF INC/IL
$5.5M5,564,290 shBAKER BROS. ADVISORS LP
$2.7M2,784,792 shVANGUARD CAPITAL MANAGEMENT LLC
$2.1M2,158,831 shTWO SIGMA INVESTMENTS, LP
$1.9M1,949,604 shRENAISSANCE TECHNOLOGIES LLC
$1.3M1,326,799 shACADIAN ASSET MANAGEMENT LLC
$1.3M1,305,840 shDeer Management Co. LLC
$1.2M1,245,504 shMILLENNIUM MANAGEMENT LLC
$1.1M1,163,611 shJACOBS LEVY EQUITY MANAGEMENT, INC
$1.0M1,049,806 sh
| Fund | Value | Shares |
|---|---|---|
| Lynx1 Capital Management LP | $7.9M | 8,019,148 |
| BVF INC/IL | $5.5M | 5,564,290 |
| BAKER BROS. ADVISORS LP | $2.7M | 2,784,792 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.1M | 2,158,831 |
| TWO SIGMA INVESTMENTS, LP | $1.9M | 1,949,604 |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | 1,326,799 |
| ACADIAN ASSET MANAGEMENT LLC | $1.3M | 1,305,840 |
| Deer Management Co. LLC | $1.2M | 1,245,504 |
| MILLENNIUM MANAGEMENT LLC | $1.1M | 1,163,611 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1.0M | 1,049,806 |
Companies Similar to TCRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
PROKIDNEY CORP.
Instil Bio, Inc.
Foghorn Therapeutics Inc.
Atai Beckley N.V.
Kymera Therapeutics, Inc.
X4 Pharmaceuticals, Inc
Upstream Bio, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TCRX on your watchlist
Track score changes the day TScan Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TCRX a good stock to buy?
13F Pro's AI-powered analysis of TScan Therapeutics, Inc. (TCRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TCRX are available on the TCRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TCRX is classified as a small company.
Which hedge funds own TCRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TCRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TScan Therapeutics, Inc.'s investment landscape.